Metabolic Disturbances in Diabetes

Textbook of Diabetes: Fourth Edition

Volumn , Issue , 2010, Pages 215-226

  Vella, Adrian ^a   Rizza, Robert A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Carbohydrate metabolism; Carbohydrate metabolism in type 1 diabetes; Counter regulatory hormones; Diabetic ketoacidosis; Impaired fasting glucose IFG; Lipid metabolism in type 1 and type 2 diabetes; Protein metabolism in type 1 and type 2 diabetes

Indexed keywords

EID: 84870458235     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444324808.ch13     Document Type: Chapter

References (141)

1. McGarry JD. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 1992; 258: 766-770.
2. Gale EA. Declassifying diabetes. Diabetologia 2006; 49: 1989-1995.
3. Rothman DL, Magnusson I, Katz LD, Shulman RG, Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 1991; 254: 573-576.
4. Ferrannini E, Groop LC. Hepatic glucose production in insulinresistant states. Diabetes Metab Rev 1989; 5: 711-726.
5. Andres R, Cader G, Zierler KL. The quantitatively minor role of carbohydrate in oxidative metabolism by skeletal muscle in intact man in the basal state: measurements of oxygen and glucose uptake and carbon dioxide and lactate production in the forearm. J Clin Invest 1956; 35: 671-682.
6. Dagenais GR, Tancredi RG, Zierler KL. Free fatty acid oxidation by forearm muscle at rest, and evidence for an intramuscular lipid pool in the human forearm. J Clin Invest 1976; 58: 421-431.
7. Consoli A, Nurjhan N, Reilly JJ, Jr., Bier DM, Gerich JE. Contribution of liver and skeletal muscle to alanine and lactate metabolism in humans. Am J Physiol 1990; 259: E677-684.
8. Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 1981; 240: E630-639.
9. Butler PC, Rizza RA. Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 1991; 40: 73-81.
10. Radziuk J, Norwich KH, Vranic M. Experimental validation of measurements of glucose turnover in nonsteady state. Am J Physiol 1978; 234: E84-93.
11. Ferrannini E, Bjorkman O, Reichard GA Jr, Pilo A, Olsson M, Wahren J, et al. The disposal of an oral glucose load in healthy subjects: a quantitative study. Diabetes, 1985; 34: 580-588.
12. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes, 2000; 49: 975-980.
13. Li CL, Tsai ST, Chou P. Relative role of insulin resistance and betacell dysfunction in the progression to type 2 diabetes: the Kinmen Study. Diabetes Res Clin Pract, 2003; 59: 225-232.
14. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE. Beta-cell function is a major contributor to oral glucose tolerance in high-risk relatives of four ethnic groups in the US. Diabetes, 2002; 51: 2170-2178.
15. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes, 1999; 48: 2197-2203.
16. Kim DJ, Lee MS, Kim KW, Lee MK. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism, 2001; 50: 590-593.
17. Bock G, Dalla Man C, Campioni M, Chittilapilly E, Basu R, Toffolo G, et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes, 2006; 55: 3536-3549.
18. Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, et al. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med, 2005; 353: 1454-1462.
19. Dinneen SF, Maldonado D 3rd, Leibson CL, Klee GG, Li H, Melton LJ 3rd, et al. Effects of changing diagnostic criteria on the risk of developing diabetes. Diabetes Care, 1998; 21: 1408-1413.
20. Dinneen SF. Mechanism of postprandial hyperglycaemia in diabetes mellitus. Eur J Gastroenterol Hepatol, 1995; 7: 724-729.
21. Dinneen S, Gerich J, Rizza R. Carbohydrate metabolism in noninsulin -dependent diabetes mellitus. N Engl J Med, 1992; 327: 707-713.
22. Moore MC, Cherrington AD, Cline G, Pagliassotti MJ, Jones EM, Neal DW, et al. Sources of carbon for hepatic glycogen synthesis in the conscious dog. J Clin Invest, 1991; 88: 578-587.
23. Youn JH, Bergman RN. Enhancement of hepatic glycogen by gluconeogenic precursors: substrate flux or metabolic control? Am J Physiol, 1990; 258: E899-906.
24. Adkins A, Basu R, Persson M, Dicke B, Shah P, Vella A, et al. Higher insulin concentrations are required to suppress gluconeogenesis than glycogenolysis in nondiabetic humans. Diabetes, 2003; 52: 2213-2220.
25. Vardi P, Crisa L, Jackson RA. Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia, 1991; 34: 93-102.
26. Vialettes B, Mattei-Zevaco C, Badier C, Ramahandridona G, Lassmann-Vague V, Vague P. Low acute insulin response to intravenous glucose: a sensitive but non-specific marker of early stages of type 1 (insulin-dependent) diabetes. Diabetologia, 1988; 31: 592-596.
27. Yki-Jarvinen H, Koivisto VA. Natural course of insulin resistance in type I diabetes. N Engl J Med, 1986; 315: 224-230.
28. Yki-Jarvinen H, Koivisto VA. Insulin sensitivity in newly diagnosed type 1 diabetics after ketoacidosis and after three months of insulin therapy. J Clin Endocrinol Metab, 1984; 59: 371-378.
29. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin -dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1982; 23: 313-319.
30. Nuutila P, Knuuti J, Ruotsalainen U, Koivisto VA, Eronen E, Teras M, et al. Insulin resistance is localized to skeletal but not heart muscle in type 1 diabetes. Am J Physiol, 1993; 264: E756-762.
31. Yki-Jarvinen H, Sahlin K, Ren JM, Koivisto VA. Localization of rate-limiting defect for glucose disposal in skeletal muscle of insulin-resistant type 1 diabetic patients. Diabetes, 1990; 39: 157-167.
32. Hother-Nielsen O, Schmitz O, Bak J, Beck-Nielsen H. Enhanced hepatic insulin sensitivity, but peripheral insulin resistance in patients with type 1 (insulin-dependent) diabetes. Diabetologia, 1987; 30: 834-840.
33. Vella A, Shah P, Basu R, Basu A, Camilleri M, Schwenk WF, et al. Type I diabetes mellitus does not alter initial splanchnic glucose extraction or hepatic UDP-glucose flux during enteral glucose administration. Diabetologia, 2001; 44: 729-737.
34. Hjollund E, Pedersen O, Richelsen B, Beck-Nielsen H, Sorensen NS. Glucose transport and metabolism in adipocytes from newly diagnosed untreated insulin-dependent diabetics: severely impaired basal and postinsulin binding activities. J Clin Invest, 1985; 76: 2091-2096.
35. Pedersen O, Hjollund E. Insulin receptor binding to fat and blood cells and insulin action in fat cells from insulin-dependent diabetics. Diabetes, 1982; 31: 706-715.
36. Podskalny JM, Kahn CR. Insulin binding and activation of glycogen synthase in fibroblasts from type 1 (insulin-dependent) diabetic patients. Diabetologia, 1982; 23: 431-435.
37. Eckel RH, Fujimoto WY. Insulin-stimulated glucose uptake, leucine incorporation into protein, and uridine incorporation into RNA in skin fibroblast cultures from patients with diabetes mellitus. Diabetologia, 1981; 20: 186-189.
38. Yki-Jarvinen H, Koivisto VA. Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes. J Clin Endocrinol Metab, 1984; 58: 659-666.
39. Lager I, Lonnroth P, von Schenck H, Smith U. Reversal of insulin resistance in type 1 diabetes after treatment with continuous subcutaneous insulin infusion. Br Med J (Clin Res Ed), 1983; 287: 1661-1664.
40. Rizza RA, Mandarino LJ, Genest J, Baker BA, Gerich JE. Production of insulin resistance by hyperinsulinaemia in man. Diabetologia, 1985; 28: 70-75.
41. Pehling G, Tessari P, Gerich JE, Haymond MW, Service FJ, Rizza RA. Abnormal meal carbohydrate disposition in insulin-dependent diabetes: relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest, 1984; 74: 985-991.
42. Gerich JE, Lorenzi M, Karam JH, Schneider V, Forsham PH. Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus. JAMA, 1975; 234: 159-155.
43. Hwang JH, Perseghin G, Rothman DL, Cline GW, Magnusson I, Petersen KF, et al. Impaired net hepatic glycogen synthesis in insulin -dependent diabetic subjects during mixed meal ingestion: a 13C nuclear magnetic resonance spectroscopy study. J Clin Invest, 1995; 95: 783-787.
44. Cline GW, Rothman DL, Magnusson I, Katz LD, Shulman GI. 13C-nuclear magnetic resonance spectroscopy studies of hepatic glucose metabolism in normal subjects and subjects with insulin-dependent diabetes mellitus. J Clin Invest, 1994; 94: 2369-2376.
45. Yki-Jarvinen H, Helve E, Koivisto VA. Relationship between oral glucose tolerance and insulin sensitivity in healthy man and type 1 diabetic patients. Acta Endocrinol (Copenh), 1986; 112: 355-360.
46. Hansen IL, Cryer PE, Rizza RA. Comparison of insulin-mediated and glucose-mediated glucose disposal in patients with insulin-dependent diabetes mellitus and in nondiabetic subjects. Diabetes, 1985; 34: 751-755.
47. Benn JJ, Bozzard SJ, Kelley D, Mitrakou A, Aoki T, Sorensen J, et al. Persistent abnormalities of the metabolism of an oral glucose load in insulin-treated type I diabetics. Metabolism, 1989; 38: 1047-1055.
48. Fujita Y, Kojima H, Hidaka H, Fujimiya M, Kashiwagi A, Kikkawa R. Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. Diabetologia, 1998; 41: 1459-1466.
49. Burant CF, Flink S, DePaoli AM, Chen J, Lee WS, Hediger MA, et al. Small intestine hexose transport in experimental diabetes: increased transporter mRNA and protein expression in enterocytes. J Clin Invest, 1994; 93: 578-585.
50. Vauhkonen I, Niskanen L, Vanninen E, Kainulainen S, Uusitupa M, Laakso M. Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited: metabolic studies on offspring of diabetic probands. J Clin Invest, 1998; 101: 86-96.
51. O'Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med, 1988; 318: 1225-1230.
52. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med, 2001; 345: 971-980.
53. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest, 1999; 104: 787-794.
54. Leahy JL. Natural history of beta-cell dysfunction in NIDDM. Diabetes Care, 1990; 13: 992-1010.
55. Johnson KH, O'Brien TD, Betsholtz C, Westermark P. Islet amyloid polypeptide: mechanisms of amyloidogenesis in the pancreatic islets and potential roles in diabetes mellitus. Laboratory investigation: a journal of technical methods and pathology. 1992; 66: 522-535.
56. Kawanishi H, Akazawa Y, Machii B. Islets of Langerhans in normal and diabetic humans: ultrastructure and histochemistry, with special reference to hyalinosis. Acta Pathol Jpn, 1966; 16: 177-197.
57. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest, 1996; 97: 2351-2361.
58. McMahon M, Marsh HM, Rizza RA. Effects of basal insulin supplementation on disposition of mixed meal in obese patients with NIDDM. Diabetes, 1989; 3 8: 291-303.
59. Schirra J, Kuwert P, Wank U, Leicht P, Arnold R, Goke B, et al. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians, 1997; 109: 84-97.
60. Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes, 1990; 39: 1381-1390.
61. Basu A, Caumo A, Bettini F, Gelisio A, Alzaid A, Cobelli C, et al. Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using anoptimized minimal model independent protocol. Diabetes, 1997; 46: 421-432.
62. Nielsen MF, Basu R, Wise S, Caumo A, Cobelli C, Rizza RA. Normal glucose-induced suppression of glucose production but impaired stimulation of glucose disposal in type 2 diabetes: evidence for a concentration-dependent defect in uptake. Diabetes, 1998; 47: 1735-1747.
63. Frank JW, Camilleri M, Thomforde GM, Dinneen SF, Rizza RA. Effects of glucagon on postprandial carbohydrate metabolism in nondiabetic humans. Metabolism, 1998; 47: 7-12.
64. Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol, 1999; 277: E283-290.
65. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab, 2000; 85: 4053-4059.
66. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, et al. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia, 1991; 34: 52-54.
67. Hiddinga HJ, Eberhardt NL. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells. Am J Pathol, 1999; 154: 1077-1088.
68. O'Brien TD, Butler PC, Kreutter DK, Kane LA, Eberhardt NL. Human islet amyloid polypeptide expression in COS-1 cells: a model of intracellular amyloidogenesis. Am J Pathol, 1995; 147: 609-616.
69. Lugari R, Dell'Anna C, Ugolotti D, Dei Cas A, Barilli AL, Zandomeneghi R, et al. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. Horm Metab Res, 2000; 32: 424-428.
70. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 2001; 50: 609-613.
71. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med, 2000; 17: 713-719.
72. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia, 1996; 39: 1546-1553.
73. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med, 1992; 326: 1316-1322.
74. Gutniak MK, Linde B, Holst JJ, Efendic S. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care, 1994; 17: 1039-1044.
75. Naslund E, Gutniak M, Skogar S, Rossner S, Hellstrom PM. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr, 1998; 68: 525-530.
76. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon -like peptide 1 (7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes, 2000; 49: 611-617.
77. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, et al. Glucose and free fatty acid metabolism in non -insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest, 1989; 84: 205-213.
78. Firth R, Bell P, Rizza R. Insulin action in non-insulin-dependent diabetes mellitus: the relationship between hepatic and extrahepatic insulin resistance and obesity. Metabolism, 1987; 36: 1091-1095.
79. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev, 1998; 19: 477-490.
80. Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med, 1989; 321: 337-343.
81. Basu R, Schwenk WF, Rizza RA. Both fasting glucose production and disappearance are abnormal in people with "mild" and "severe" type 2 diabetes. Am J Physiol Endocrinol Metab, 2004; 287: E55-62.
82. Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA. Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus: role of hepatic and extrahepatic tissues. J Clin Invest, 1986; 77: 1525-1532.
83. Basu A, Basu R, Shah P, Vella A, Johnson CM, Jensen M, et al. Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity. Diabetes, 2001; 50: 1351-1362.
84. Basu A, Basu R, Shah P, Vella A, Johnson CM, Nair KS, et al. Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. Diabetes, 2000; 49: 272-283.
85. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev, 2002; 23: 201-229.
86. Roust LR, Jensen MD. Postprandial free fatty acid kinetics are abnormal in upper body obesity. Diabetes, 1993; 42: 1567-1573.
87. Saloranta C, Franssila-Kallunki A, Ekstrand A, Taskinen MR, Groop L. Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia, 1991; 34: 409-415.
88. Klein S, Wolfe RR. Carbohydrate restriction regulates the adaptive response to fasting. Am J Physiol, 1992; 262: E631-636.
89. Kelley DE, Mokan M, Simoneau JA, Mandarino LJ. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J Clin Invest, 1993; 92: 91-98.
90. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest, 1983; 72: 1737-1747.
91. Miles JM, Haymond MW, Nissen SL, Gerich JE. Effects of free fatty acid availability, glucagon excess, and insulin deficiency on ketone body production in postabsorptive man. J Clin Invest, 1983; 71: 1554-1561.
92. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia, 1995; 38: 337-343.
93. Jensen MD, Haymond MW, Gerich JE, Cryer PE, Miles JM. Lipolysis during fasting: decreased suppression by insulin and increased stimulation by epinephrine. J Clin Invest, 1987; 79: 207-213.
94. Kanaley JA, Haymond MW, Jensen MD. Effects of exercise and weight loss on leucine turnover in different types of obesity. Am J Physiol, 1993; 264: E687-692.
95. Ruegemer JJ, Squires RW, Marsh HM, Haymond MW, Cryer PE, Rizza RA, et al. Differences between prebreakfast and late afternoon glycemic responses to exercise in IDDM patients. Diabetes Care, 1990; 13: 104-110.
96. Schneider SH, Vitug A, Ananthakrishnan R, Khachadurian AK. Impaired adrenergic response to prolonged exercise in type 1 diabetes. Metabolism, 1991; 40: 1219-1225.
97. Wahren J, Sato Y, Ostman J, Hagenfeldt L, Felig P. Turnover and splanchnic metabolism of free fatty acids and ketones in insulin-dependent diabetics at rest and in response to exercise. J Clin Invest, 1984; 73: 1367-1376.
98. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes, 1988; 37: 1020-1024.
99. Coppack SW, Evans RD, Fisher RM, Frayn KN, Gibbons GF, Humphreys SM, et al. Adipose tissue metabolism in obesity: lipase action in vivo before and after a mixed meal. Metabolism, 1992; 41: 264-272.
100. Campbell PJ, Carlson MG, Nurjhan N. Fat metabolism in human obesity. Am J Physiol, 1994; 266: E600-605.
101. Nurjhan N, Campbell PJ, Kennedy FP, Miles JM, Gerich JE. Insulin dose-response characteristics for suppression of glycerol release and conversion to glucose in humans. Diabetes, 1986; 35: 1326-1331.
102. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest, 1996; 97: 2859-2865.
103. Shah P, Vella A, Basu A, Basu R, Adkins A, Schwenk WF, et al. Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans. Diabetes, 2002; 51: 301-310.
104. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes, 1997; 46: 3-10.
105. Moller N, Nair KS. Diabetes and protein metabolism. Diabetes, 2008; 57: 3-4.
106. Walsh CH, Soler NG, James H, Harvey TC, Thomas BJ, Fremlin JH, et al. Studies in whole body potassium and whole body nitrogen in newly diagnosed diabetics. Q J Med, 1976; 45: 295-301.
107. Atchley DW, Loeb RF, Richards DW, Benedict EM, Driscoll ME. On diabetic acidosis: a detailed study of electrolyte balances following the withdrawal and reestablishment of insulin therapy. J Clin Invest, 1933; 12: 297-326.
108. Felig P, Wahren J, Sherwin R, Palaiologos G. Amino acid and protein metabolism in diabetes mellitus. Arch Intern Med, 1977; 137: 507-513.
109. Nair KS, Garrow JS, Ford C, Mahler RF, Halliday D. Effect of poor diabetic control and obesity on whole body protein metabolism in man. Diabetologia, 1983; 25: 400-403.
110. Charlton MR, Adey DB, Nair KS. Evidence for a catabolic role of glucagon during an amino acid load. J Clin Invest, 1996; 98: 90-99.
111. Nair KS, Ford GC, Ekberg K, Fernqvist-Forbes E, Wahren J. Protein dynamics in whole body and in splanchnic and leg tissues in type 1 diabetic patients. J Clin Invest, 1995; 95: 2926-2937.
112. Halvatsiotis PG, Turk D, Alzaid A, Dinneen S, Rizza RA, Nair KS. Insulin effect on leucine kinetics in type 2 diabetes mellitus. Diabetes Nutr Metab, 2002; 15: 136-142.
113. Luzi L, Petrides AS, De Fronzo RA. Different sensitivity of glucose and amino acid metabolism to insulin in NIDDM. Diabetes, 1993; 42: 1868-1877.
114. Gougeon R, Marliss EB, Jones PJ, Pencharz PB, Morais JA. Effect of exogenous insulin on protein metabolism with differing nonprotein energy intakes in type 2 diabetes mellitus. Int J Obes Relat Metab Disord, 1998; 22: 250-261.
115. Gougeon R, Styhler K, Morais JA, Jones PJ, Marliss EB. Effects of oral hypoglycemic agents and diet on protein metabolism in type 2 diabetes. Diabetes Care, 2000; 23: 1-8.
116. Gougeon R, Morais JA, Chevalier S, Pereira S, Lamarche M, Marliss EB. Determinants of whole-body protein metabolism in subjects with and without type 2 diabetes. Diabetes Care, 2008; 31: 128-133.
117. Pereira S, Marliss EB, Morais JA, Chevalier S, Gougeon R. Insulin resistance of protein metabolism in type 2 diabetes. Diabetes, 2008; 57: 56-63.
118. Hughes K, Choo M, Kuperan P, Ong CN, Aw TC. Cardiovascular risk factors in non-insulin-dependent diabetics compared to non-diabetic controls: a population-based survey among Asians in Singapore. Atherosclerosis, 1998; 136: 25-31.
119. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes, 2000; 49: 633-639.
120. Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes, 2002; 51: 2968-2974.
121. Seino Y, Ikeda M, Kurahachi H, Taminato T, Sakurai H, Goto Y, et al. Failure of suppress plasma glucagon concentrations by orally administered glucose in diabetic patients after treatment. Diabetes, 1978; 27: 1145-1150.
122. Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Karam JH, et al. Prevention of human diabetic ketoacidosis by somatostatin: evidence for an essential role of glucagon. N Engl J Med, 1975; 292: 985-989.
123. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med, 1970; 283: 109-115.
124. Raskin P, Unger RH. Effect of insulin therapy on the profiles of plasma immunoreactive glucagon in juvenile-type and adult-type diabetics. Diabetes, 1978; 27: 411-419.
125. Stagner JI, Samols E, Koerker DJ, Goodner CJ. Perfusion with anti-insulin gamma globulin indicates a B to A to D cellular perfusion sequence in the pancreas of the rhesus monkey, Macaca mulatta. Pancreas, 1992; 7: 26-29.
126. Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes, 1994; 43: 1426-1434.
127. Rizza R, Verdonk C, Miles J, Service FJ, Gerich J. Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man. J Clin Invest, 1979; 63: 1119-1123.
128. Cherrington AD, Williams PE, Shulman GI, Lacy WW. Differential time course of glucagon's effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes, 1981; 30: 180-187.
129. Bolli G, De Feo P, De Cosmo S, Perriello G, Angeletti G, Ventura MR, et al. Effects of long-term optimization and short-term deterioration of glycemic control on glucose counterregulation in type 1 diabetes mellitus. Diabetes, 1984; 33: 394-400.
130. Bolli G, Cartechini MG, Compagnucci P, Malvicini S, De Feo P, Santeusanio F, et al. Effect of metabolic control on urinary excretion and plasma levels of catecholamines in diabetics. Horm Metab Res, 1979; 11: 493-497.
131. Rizza RA, Cryer PE, Haymond MW, Gerich JE. Adrenergic mechanisms for the effects of epinephrine on glucose production and clearance in man. J Clin Invest, 1980; 65: 682-689.
132. Gerich JE, Lorenzi M, Tsalikian E, Karam JH. Studies on the mechanism of epinephrine-induced hyperglycemia in man: evidence for participation of pancreatic glucagon secretion. Diabetes, 1976; 25: 65-71.
133. Avogaro A, Valerio A, Gnudi L, Maran A, Miola M, Duner E, et al. The effects of different plasma insulin concentrations on lipolytic and ketogenic responses to epinephrine in normal and type 1 (insulin-dependent) diabetic humans. Diabetologia, 1992; 35: 129-138.
134. Dinneen S, Alzaid A, Miles J, Rizza R. Effects of the normal nocturnal rise in cortisol on carbohydrate and fat metabolism in IDDM. Am J Physiol, 1995; 268: E595-603.
135. Schade DS, Eaton RP, Standefer J. Modulation of basal ketone body concentration by cortisol in diabetic man. J Clin Endocrinol Metab, 1978; 47: 519-528.
136. Hayford JT, Danney MM, Hendrix JA, Thompson RG. Integrated concentration of growth hormone in juvenile-onset diabetes. Diabetes, 1980; 29: 391-398.
137. Hansen AP. Effect of insulin on growth-hormone secretion in juvenile diabetics. Lancet, 1972; 2: 432-433.
138. Press M, Tamborlane WV, Sherwin RS. Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes. N Engl J Med, 1984; 310: 810-815.
139. Miles JM, Rizza RA, Haymond MW, Gerich JE. Effects of acute insulin deficiency on glucose and ketone body turnover in man: evidence for the primacy of overproduction of glucose and ketone bodies in the genesis of diabetic ketoacidosis. Diabetes, 1980; 29: 926-930.
140. Cryer PE, White NH, Santiago JV. The relevance of glucose counterregulatory systems to patients with insulin-dependent diabetes mellitus. Endocr Rev, 1986; 7: 131-139.
141. Butkiewicz EK, Leibson CL, O'Brien PC, Palumbo PJ, Rizza RA. Insulin therapy for diabetic ketoacidosis: bolus insulin injection versus continuous insulin infusion. Diabetes Care, 1995; 18: 1187-1190.